. 2021 Apr 5;4(3):1195–1203. doi: 10.1021/acsptsci.1c00062

Table 2. Comparison of 9L, U87 ΔEGFR, and DU145 Cell Uptake of [¹⁸F]5, anti-cis-3,4-[¹⁸F]-DFACPC, syn-cis-3,4-[¹⁸F]-DFACPC, and anti-3-[¹⁸F]-FACBC without Inhibitors after 30 min of Incubation^a.

tracer	9L	U87 ΔEGFR	DU145
[¹⁸F]5	23.5 ± 1.5	6.45 ± 0.46	34.0 ± 4.1
anti-cis-3,4-[¹⁸F]-DFACPC	23.4 ± 3.0	7.53 ± 1.2	17.7 ± 3.0
syn-cis-3,4-[¹⁸F]-DFACPC	7.82 ± 0.37	4.29 ± 0.29	12.2 ± 0.46
anti-3-[¹⁸F]-FACBC	23.2 ± 2.6	6.19 ± 1.22	20.2 ± 3.4

Data are presented as percent ligand uptake of the initial dose per 0.5 million cells (%ID/5 × 10⁵ cells) ± standard deviation (n = 3–4) and normalized for the dose and number of cells.

Table 2. Comparison of 9L, U87 ΔEGFR, and DU145 Cell Uptake of [18F]5, anti-cis-3,4-[18F]-DFACPC, syn-cis-3,4-[18F]-DFACPC, and anti-3-[18F]-FACBC without Inhibitors after 30 min of Incubationa.

Table 2. Comparison of 9L, U87 ΔEGFR, and DU145 Cell Uptake of [¹⁸F]5, anti-cis-3,4-[¹⁸F]-DFACPC, syn-cis-3,4-[¹⁸F]-DFACPC, and anti-3-[¹⁸F]-FACBC without Inhibitors after 30 min of Incubation^a.